{
    "clinical_study": {
        "@rank": "43809", 
        "arm_group": {
            "arm_group_label": "gastric adenocarcinoma", 
            "description": "No protocol specific interventions. Both palliative or curative treatment allowed."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Assessing quality of life in patients who are undergoing cancer treatment may\n      help determine the effect of treatment on these patients.\n\n      PURPOSE: Clinical trial to study the effectiveness of a quality of life assessment in\n      patients who are receiving treatment for stomach cancer."
        }, 
        "brief_title": "Assessing Quality of Life of Patients With Stomach Cancer", 
        "completion_date": {
            "#text": "January 2004", 
            "@type": "Actual"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the scale structure, reliability, and validity of the tumor-specific\n           questionnaire, QLQ-STO22, in assessing the quality of life of patients with gastric\n           cancer.\n\n        -  Determine the questionnaire's sensitivity to change in clinical health status in these\n           patients.\n\n      OUTLINE: Patients are stratified according to type of treatment (potentially curative vs\n      potentially palliative), disease stage (local and locoregional vs metastatic), Karnofsky\n      performance status (less than 80% vs more than 80%), and initial weight gain (none vs less\n      than 10% of total body weight vs 10% or more of total body weight).\n\n        -  Curatively Treated Group: Quality of life is assessed at 4 weeks prior to surgery and 3\n           months after surgery in patients receiving total or partial gastrectomy with curative\n           intent; at 4 weeks prior to chemotherapy and/or radiotherapy, 4 weeks prior to surgery,\n           and 3 months after surgery in patients receiving neoadjuvant chemotherapy and/or\n           radiotherapy followed by total or partial gastrectomy with curative intent; at 4 weeks\n           prior to chemotherapy and/or radiotherapy and 6 weeks after completion of therapy in\n           patients receiving adjuvant chemotherapy and/or radiotherapy following total or partial\n           gastrectomy; and at 4 weeks prior to therapy and 3 months after completion of therapy\n           in patients receiving endoscopic mucosal resection or laparoscopic wedge resection.\n\n        -  Palliatively Treated Group: Quality of life is assessed at 3 weeks prior to palliative\n           therapy and 4 weeks after beginning palliative therapy.\n\n      PROJECTED ACCRUAL: Approximately 220 patients (110 per group) will be accrued for this study\n      within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed gastric adenocarcinoma\n\n          -  Patients treated with curative intent according to one of the following criteria:\n\n               -  Plan to undergo total or partial gastrectomy with curative intent\n\n               -  Plan to receive neoadjuvant chemotherapy and/or radiotherapy followed by total\n                  or partial gastrectomy with curative intent\n\n               -  Prior total or partial gastrectomy with curative intent and currently receiving\n                  adjuvant chemotherapy and/or radiotherapy\n\n               -  Prior endoscopic mucosal resection or laparoscopic wedge resection of early\n                  gastric cancer OR\n\n          -  Patients with initial diagnosis of gastric cancer or recurrent disease with plans to\n             receive one of the following therapies with palliative intent:\n\n               -  Total or partial gastrectomy or bypass procedure\n\n               -  Endoscopic procedure (e.g., stent insertion)\n\n               -  Chemotherapy and/or radiotherapy\n\n               -  Supportive measures only\n\n          -  No concurrent enrollment on other quality of life study that would interfere with\n             this study\n\n          -  Not previously enrolled on this study\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Any age\n\n        Performance status:\n\n          -  Any performance status\n\n        Life expectancy:\n\n          -  At least 2 months for patients treated with curative intent\n\n          -  At least 4 weeks for patients treated with palliative intent\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  No other concurrent malignancies except basal cell carcinoma of the skin\n\n          -  No mental impairment that would preclude completion of questionnaire\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude study compliance\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n        Surgery:\n\n          -  See Disease Characteristics"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study sample will be composed of a consecutive series of patients with gastric cancer\n        meeting the eligibility criteria in each participating centre. The definition of gastric\n        cancer is adenocarcinoma of the stomach, and includes all tumours of the fundus, body and\n        antrum, linitis plastica and tumours of the cardia that infiltrate the gastro-oesophageal\n        junction and distal oesophagus from below; classified as type III according to Siewert\n        (1998. The study sample will be stratified by treatment - potentially curative and purely\n        palliative."
            }
        }, 
        "enrollment": {
            "#text": "267", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00020826", 
            "org_study_id": "EORTC-15001-40003", 
            "secondary_id": [
                "EORTC-15001", 
                "EORTC-40003"
            ]
        }, 
        "intervention": {
            "arm_group_label": "gastric adenocarcinoma", 
            "description": "QLQ-C30 questionnaire administered. STO22 questionnaire administered.", 
            "intervention_name": "quality-of-life assessment", 
            "intervention_type": "Other", 
            "other_name": [
                "QLQ-C30 questionnaire administered.", 
                "STO22 questionnaire administered."
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "adenocarcinoma of the stomach", 
        "lastchanged_date": "August 24, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-15001"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vandoeuvre-les-Nancy", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "Centre Alexis Vautrin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-10117"
                    }, 
                    "name": "Universitaetsklinikum Charite"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "zip": "D-35033"
                    }, 
                    "name": "University of Marburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "zip": "31080"
                    }, 
                    "name": "Hospital De Navarra"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg (Goteborg)", 
                        "country": "Sweden", 
                        "zip": "S-413 45"
                    }, 
                    "name": "Sahlgrenska University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "BS2 8ED"
                    }, 
                    "name": "Bristol Haematology and Oncology Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "G4 0SF"
                    }, 
                    "name": "Royal Infirmary"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Spain", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module (The QLQ-STO22) In Assessing The Quality Of Life Of Patients With Gastric Cancer", 
        "other_outcome": [
            {
                "description": "Proportion of completed versus expected QoL questionnaires", 
                "measure": "compliance", 
                "safety_issue": "No", 
                "time_frame": "at the same timepoints when the QoL questionnaires are completed"
            }, 
            {
                "description": "correlations between the different established scales of the QLQ-C30 and the hypothesized STO22 scales will be calculated.", 
                "measure": "correlation between QLQ-C30 and STO22 scores", 
                "safety_issue": "No", 
                "time_frame": "before and after treatment"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "University Hospitals Bristol NHS Trust", 
                "last_name": "Jane Blazeby, MB, CHB, FRCS, BSc, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Centre Alexis Vautrin", 
                "last_name": "Thierry Conroy, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Quality of life scores will be evaluated for psychometric validity by:\nScale structure using multi-trait scaling analysis\nReliability using tests of internal consistency\nTest-retest reliability in patients recruited in the UK\nValidity using inter-scale correlations and known group comparisons\nSensitivity to change using two measurements of Quality of Life and ANOVA to look for the significance of changes in quality of life scores as a function of observed changes in clinical status over time.", 
            "measure": "psychometric validity of the STO22 module", 
            "safety_issue": "No", 
            "time_frame": "The EORTC QLQ-C30 and the gastric cancer module (QLQ-STO22) will be prospectively administered once before and once after primary treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00020826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": [
            {
                "PMID": "18979141", 
                "citation": "O\u00f1ate-Oca\u00f1a LF, Alc\u00e1ntara-Pilar A, Vilar-Compte D, Garc\u00eda-Hubard G, Rojas-Castillo E, Alvarado-Aguilar S, Carrillo JF, Blazeby JM, Aiello-Crocifoglio V. Validation of the Mexican Spanish Version of the EORTC C30 and STO22 Questionnaires for the Evaluation of Health-Related Quality of Life in Patients with Gastric Cancer. Ann Surg Oncol. 2008 Nov 1; [Epub ahead of print]"
            }, 
            {
                "PMID": "19715606", 
                "citation": "Sadighi S, Montazeri A, Sedighi Z, Mohagheghi MA, Froutan H. Quality of life in patients with gastric cancer: translation and psychometric evaluation of the Iranian version of EORTC QLQ-STO22. BMC Cancer. 2009 Aug 28;9:305."
            }
        ], 
        "secondary_outcome": {
            "description": "Patients will be asked to complete a short debriefing questionnaire covering questions about the time taken to complete the EORTC QLQ-C30 and QLQ-STO22; the need for help in completing the questionnaires and querying whether any of the questionnaire items were confusing; difficult to answer or upsetting.", 
            "measure": "debriefing questionnaire information", 
            "safety_issue": "No", 
            "time_frame": "at baseline"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }, 
    "geocoordinates": {
        "Bristol Haematology and Oncology Centre": "51.455 -2.588", 
        "Centre Alexis Vautrin": "48.661 6.174", 
        "Hospital De Navarra": "42.818 -1.644", 
        "Royal Infirmary": "55.864 -4.252", 
        "Sahlgrenska University Hospital": "57.709 11.975", 
        "Universitaetsklinikum Charite": "52.524 13.406", 
        "University of Marburg": "50.802 8.767"
    }
}